Qubigen Announces a Collaboration with Viva Biotech in AI-Driven Drug Discovery
- 1 day ago
- 2 min read
Qubigen is pleased to announce a new collaboration with Viva Biotech, a global leader in AI-enabled drug discovery. Through this partnership, we will actively explore areas where traditional computational tools fall short, notably in the domain of failed (‘dark’) reaction data. The collaboration brings together Viva Biotech’s advanced Artificial Intelligence Drug Discovery (AIDD) capabilities with Qubigen’s expertise in synthetic feasibility and reaction prediction AI models. Qubigen will apply its advanced, proprietary Federated AI technology to unlock new opportunities to push the boundaries of predictive chemistry.
Unlocking the Value of Dark Reaction Data
In a recent case study, Qubigen showed that a Federated AI Engine for reaction feasibility could be tailored to client-specific data. Augmenting publicly available reaction data with a small internal dataset of genuine dark reactions, Qubigen’s Federated AI technology achieved:
130% improvement in accuracy for prediction of dark reactions (33% → 76%)
90% accuracy maintained on standard benchmark datasets
Improved balance between predicting successful and unsuccessful reactionsÂ
The study highlights how previously under-utilized experimental dark data can become a strategic AI advantage when accessed securely through Qubigen’s Federated AI platform. This collaboration reinforces a broader industry shift: the future of predictive chemistry will be driven not only by larger public datasets, but by unlocking the value of proprietary experimental knowledge.
Looking ahead, Qubigen will be working closely with Viva Biotech to develop new capabilities with a particular focus on advancing dark reaction prediction technology. By combining Viva Biotech’s strengths in AI-driven drug discovery, integrated dry-and-wet lab solutions, lab-in-the-loop workflows, and broad modality coverage with Qubigen’s expertise in reaction prediction AI and synthetic feasibility modelling, the partnership  aims to deliver next-generation AI systems that can not only design promising drugs but also more accurately predict how – and whether – they can be synthesized.
Through secure, tailored, accurate prediction of low-probability reactions, Qubigen’s Federated AI Engines are expected to improve decision-making efficiency, and accelerate drug discovery timelines.
Viva Biotech
Viva Biotech is global leader in Structure-Based Drug Discovery (SBDD), AI-driven drug discovery (AIDD), and their comprehensive CRO+CDMO service. It has established itself at the forefront of AI-powered drug design. Their ability to generate, evaluate, and optimize molecular candidates at scale represents a powerful foundation for accelerating therapeutic discovery.
Qubigen - Accelerate Drug Design Without Exposing Secrets
Qubigen builds and hosts powerful, privacy-preserving AI Engines, turning discrete client-specific data into a competitive edge. Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure Federated AI and computational modelling and chemistry platform can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.